Cross-Talk Between MAP Kinase Pathways Is Involved in IGF-Independent, IGFBP-6-Induced Rh30 Rhabdomyosarcoma Cell Migration

被引:23
作者
Fu, Ping [1 ]
Liang, Guang Jun [1 ]
Khot, Sahil S. [1 ]
Phan, Robert [1 ]
Bach, Leon A. [1 ,2 ]
机构
[1] Monash Univ, Dept Med, Cent Clin Sch, AMREP, Melbourne, Vic 3004, Australia
[2] The Alfred, Dept Endocrinol & Diabet, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
INSULIN-LIKE-GROWTH; ACTIVATED PROTEIN-KINASE; COLON-CANCER CELLS; BINDING PROTEIN-6; IN-VIVO; PLASMINOGEN-ACTIVATOR; SIGNALING PATHWAYS; JNK; CHEMOTAXIS; EXPRESSION;
D O I
10.1002/jcp.22156
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Insulin-like growth factor binding protein-6 (IGFBP-6) inhibits the tumorigenic properties of IGF-II-dependent cancer cells by directly inhibiting IGF-II actions. However, in some cases, IGFBP-6 is associated with increased cancer cell tumorigenicity, which is unlikely to be due to IGF-II inhibition. The mechanisms underlying the contradictory actions of IGFBP-6 remain unclear. We recently generated an IGFBP-6 mutant that does not bind IGFs (mIGFBP-6) to address this issue. Although RD rhabdomyosarcoma cells express IGF-II, we previously showed that mIGFBP-6 promoted migration through an IGF-independent, p38-dependent pathway. We further studied the role of MAP kinases in IGFBP-6-induced migration of Rh30 rhabdomyosarcoma cells, which also express IGF-II. In these cells, mIGFBP-6 induced chemotaxis rather than chemokinesis. Both wild-type (wt) and mIGFBP-6 transiently induced phosphorylation of ERK1/2 and JNK1, but not p38. Inhibition of ERK1/2 phosphorylation completely prevented mIGFBP-6-induced ERK1/2 activation and cell migration, whereas a JNK inhibitor partially prevented migration. Interestingly, p38 pathway inhibition completely prevented mIGFBP-6-induced ERK1/2 and JNK1 activation and migration despite mIGFBP-6 not activating p38. Furthermore, blocking the ERK1/2 pathway also inhibited mIGFBP-6-induced JNK1 activation. In contrast, IGFBP-6 had no effect on Akt phosphorylation and an Akt inhibitor had no effect on migration. These results indicate that IGFBP-6 promotes Rh30 rhabdomyosarcoma chemotaxis in an IGF-independent manner, and that MAPK signaling pathways and their cross-talk play an important role in this process. Therefore, besides decreasing Rh30 cell proliferation by inhibiting IGF-II, IGFBP-6 promotes their migration via a distinct pathway. Understanding these disparate actions of IGFBP-6 may lead to the development of novel cancer therapeutics. © 2010 Wiley-Liss, Inc.
引用
收藏
页码:636 / 643
页数:8
相关论文
共 42 条
[1]   PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO [J].
ALESSI, DR ;
CUENDA, A ;
COHEN, P ;
DUDLEY, DT ;
SALTIEL, AR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) :27489-27494
[2]   IGF-binding proteins - the pieces are failing into place [J].
Bach, LA ;
Headey, SJ ;
Norton, RS .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2005, 16 (05) :228-234
[3]   IGFBP-6 five years on; not so 'forgotten'? [J].
Bach, LA .
GROWTH HORMONE & IGF RESEARCH, 2005, 15 (03) :185-192
[4]   The specificities of protein kinase inhibitors: an update [J].
Bain, J ;
McLauchlan, H ;
Elliott, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2003, 371 :199-204
[5]   Protein scaffolds in MAP kinase signalling [J].
Brown, Matthew D. ;
Sacks, David B. .
CELLULAR SIGNALLING, 2009, 21 (04) :462-469
[6]   MEKK1 regulates calpain-dependent proteolysis of focal adhesion proteins for rear-end detachment of migrating fibroblasts [J].
Cuevas, BD ;
Abell, AN ;
Witowsky, JA ;
Yujiri, T ;
Johnson, NL ;
Kesavan, K ;
Ware, M ;
Jones, PL ;
Weed, SA ;
DeBiasi, RL ;
Oka, Y ;
Tyler, KL ;
Johnson, GL .
EMBO JOURNAL, 2003, 22 (13) :3346-3355
[7]   Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].
Davies, SP ;
Reddy, H ;
Caivano, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105
[8]   MAP kinase signalling pathways in cancer [J].
Dhillon, A. S. ;
Hagan, S. ;
Rath, O. ;
Kolch, W. .
ONCOGENE, 2007, 26 (22) :3279-3290
[9]   The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity [J].
Ebisuya, M ;
Kondoh, K ;
Nishida, E .
JOURNAL OF CELL SCIENCE, 2005, 118 (14) :2997-3002
[10]   Insulin-like growth factor ligands, receptors, and binding proteins in cancer [J].
Foulstone, E ;
Prince, S ;
Zaccheo, O ;
Burns, JL ;
Harper, J ;
Jacobs, C ;
Church, D ;
Hassan, AB .
JOURNAL OF PATHOLOGY, 2005, 205 (02) :145-153